Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

Rhea-AI Summary

Intensity Therapeutics (NASDAQ: INTS) has announced a collaboration with breast cancer survivor and author Christine Handy to raise awareness about early-stage breast cancer treatment options. Handy, whose book "Walk Beside Me" inspired the award-winning film "Hello Beautiful," will work with Intensity to develop educational resources about emerging therapies, including the company's investigational drug INT230-6.

The company is currently conducting the Phase 2 INVINCIBLE-4 trial for triple-negative breast cancer patients in pre-surgical settings. Additionally, Intensity will present a poster at the upcoming ASCO 2025 Annual Meeting about their Phase 3 INVINCIBLE-3 study, which evaluates INT230-6 as a monotherapy for soft tissue sarcomas.

SHELTON, Conn., May 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral investigational cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces a collaboration to educate patients with early stage breast cancer about potential new therapeutic options with model, author, executive producer, speaker, and breast cancer survivor Christine Handy. The film, Hello Beautiful, an adaptation of Ms. Handy's award-winning novel Walk Beside Me, recently won the Golden Palm Award at the Beverly Hills Film Festival.

"Earlier this year, I discovered Intensity Therapeutics and their promising data on a novel tumor-injection therapy, offering hope for those navigating the challenges of breast cancer treatment. As someone who has experienced this journey firsthand, I'm passionate about supporting women diagnosed with early-stage breast cancer. I'm thrilled to partner with Intensity Therapeutics to develop educational resources on breast cancer treatment options and emerging therapies. My book, Walk Beside Me, inspired the film Hello Beautiful, which follows a protagonist grappling with the harsh realities of today's cancer treatments. The story is a beacon of hope, envisioning a future beyond cancer. With innovative treatments like Intensity's investigational drug INT230-6 on the horizon, women can look forward to more effective and compassionate options," said Christine Handy.

"It is an honor to be collaborating with a patient advocate such as Christine Handy. She has been on an incredible journey since her diagnosis of early-stage breast cancer in 2012. Christine offers a positive story to patients everywhere. Christine faced a gauntlet of confusing options, fear, potential death from the treatment, pain, and uncertainty that is inherent in today's pre-surgical and post-surgical regimens. Her experience is far too common for women around the world. Christine, like us, wants patients to have a positive outlook about their future," said Lewis H. Bender, Intensity Therapeutics Founder and CEO. "Our company was founded to improve the lives of cancer patients, especially those with early-stage breast cancer, making our collaboration with Christine a natural fit. Our ongoing Phase 2, INVINCIBLE-4 trial has the potential to improve the outcome and safety of women with triple-negative breast cancer undergoing immuno/chemotherapy in the pre-surgical setting. We look forward to working with Christine to bring greater understanding to pre-surgical cancer patients everywhere of the potential for new treatments as we continue our investigational drug product development."

Handy and Bender will both attend the upcoming American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025, at McCormick Place, Chicago, Ill.

Intensity will also be presenting a poster (abstract TPS11588) on its current study in Sarcoma on Saturday, May 31, from 9:30 AM to 12:00 PM CDT at panel 66a titled, "A Multi-center, Randomized, Global Phase 3 Study to Assess the Efficacy and Safety of Intratumoral (IT) INT230-6 (SHAO, vinblastine, cisplatin) as Monotherapy Compared with Standard of Care Systemic Chemotherapy in Adults with Locally Recurrent, Inoperable, or Metastatic Soft Tissue Sarcomas (STS; INVINCIBLE-3)," during the conference.

About Christine Handy
Christine Handy is an American model, author, motivational speaker, Executive producer and breast cancer survivor. She has been a print model for over 40 years. Handy was diagnosed with an aggressive form of breast cancer on October 1, 2012. She experienced 28 rounds of chemotherapy and a double mastectomy. Handy's 2016 novel Walk Beside Me is a fictionalized story of the ordeal of a successful model who receives a breast cancer diagnosis. It was a national bestseller. In May of 2025, the independent film, Hello Beautiful, won the Golden Palm Best Picture Award at the prestigious and influential 25th Annual Beverly Hills Film Festival. The film, based on Handy's novel, was directed by Ziad Hamzeh. Michael Espinosa produced the film, and it features actress Tricia Helfer.

About Intensity Therapeutics
Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of the investigational new drug, INT230-6, to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shih the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, SAKK (the "INVINCIBLE-4 Study") (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ("pCR") is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com

Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled "Risk Factors" in the Company's SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor Relations Contact:
Justin Kulik
Justin@coreir.com
CORE IR
(516) 222-2560

Media Contact:
Jules Abraham
CORE IR
pr@coreir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-inc-to-collaborate-with-author-model-executive-producer-speaker-and-breast-cancer-survivor-christine-handy-to-raise-patient-awareness-of-early-stage-breast-cancer-treatment-options-on-the-horizon-302465288.html

SOURCE Intensity Therapeutics Inc.

FAQ

What is the purpose of Intensity Therapeutics' collaboration with Christine Handy?

The collaboration aims to educate patients with early-stage breast cancer about potential new therapeutic options, including Intensity's investigational drug INT230-6, through educational resources development.

What clinical trials is INTS currently conducting for breast cancer treatment?

Intensity Therapeutics is conducting the Phase 2 INVINCIBLE-4 trial, which studies INT230-6 for triple-negative breast cancer patients in pre-surgical settings.

What will Intensity Therapeutics (INTS) present at ASCO 2025?

Intensity will present a poster about their Phase 3 INVINCIBLE-3 study, which evaluates INT230-6 as a monotherapy for soft tissue sarcomas, on May 31, 2025.

Who is Christine Handy and what is her connection to Intensity Therapeutics?

Christine Handy is a breast cancer survivor, author, model, and speaker whose book 'Walk Beside Me' inspired the award-winning film 'Hello Beautiful.' She is partnering with Intensity Therapeutics to raise awareness about breast cancer treatment options.